Micafungin Inresa (Micafungin)

Micafungin works by inhibiting the fungal enzyme β‑1,3‑D‑glucan synthase, which is essential for building β‑1,3‑D‑glucan, a key structural component of the fungal cell wall. Blocking this enzyme compromises cell‑wall integrity, leading to osmotic instability and death of the fungal cell while sparing human cells.

The dosing regimen for Micafungin Inresa is determined by the prescribing clinician based on the specific infection, patient weight, renal and hepatic function, and treatment setting. Healthcare professionals select the appropriate dose and duration according to current clinical guidelines and individual patient factors.

Safety data for Micafungin in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus. Breastfeeding mothers should consult their physician, as the drug may be excreted in milk.

To place an order, submit an enquiry on the Micafungin Inresa product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including cold‑chain handling) and any necessary import documentation.

Micafungin belongs to the echinocandin class, which targets the fungal cell wall, whereas azoles inhibit ergosterol synthesis and polyenes bind directly to membrane sterols. Echinocandins, including Micafungin, generally have a favorable safety profile and are effective against many Candida species, including those resistant to azoles, but they are administered intravenously and are not active against all moulds.

Micafungin Inresa must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking. If a short period outside the recommended temperature range is unavoidable, ensure the product is returned to controlled storage promptly to maintain stability.

Micafungin Inresa is given as an intravenous infusion by a qualified healthcare professional. The infusion is typically administered over 30‑60 minutes, depending on the prescribed dose and patient tolerance. Administration sets should be compatible with the drug, and patients are monitored for any infusion‑related reactions during and after the infusion.

Serious adverse events include hepatotoxicity, severe hypersensitivity reactions such as anaphylaxis, and infusion‑related complications like hypotension or bronchospasm. Clinicians should monitor liver function tests regularly, observe patients during the first infusion for signs of allergic response, and be prepared to manage acute reactions promptly.

Micafungin Inresa is contraindicated in patients with known hypersensitivity to micafungin or any component of the formulation. Caution is also advised for individuals with pre‑existing severe liver disease, uncontrolled cardiac conditions, or those receiving drugs that may cause significant pharmacokinetic interactions, unless close monitoring is feasible.